The strong beat-and-raise quarter with accelerating revenue growth (23% YoY) and expanding gross margins signals improving operating leverage. Traders should watch for the Q4 FY26 adjusted EBITDA breakeven milestone and any early FY2027 guidance on the upcoming earnings call, which could drive further upside.
Price Chart
Executive Summary
Twist Bioscience reported fiscal Q3 2026 revenue of $118.4M, a 23% YoY increase and above the $114.5M consensus estimate. The company raised its full-year FY2026 revenue guidance to $456-457M, up $12M at the midpoint from prior guidance of $442-447M, while reiterating Q4 FY26 adjusted EBITDA breakeven. Gross margin expanded to 52.8%, up 120 bps sequentially, and the company posted its 14th consecutive quarter of sequential growth, reinforcing strong execution in both DSPS (+39% YoY) and NGS (+12% YoY) segments.
Key Financial Metrics
Key Facts
- Revenue of $118.4M beat consensus of $114.5M and grew 23% YoY from $96.1M.
- FY2026 revenue guidance raised to $456-457M from $442-447M, an increase of ~$12M at the midpoint.
- Gross margin improved to 52.8% from 51.6% in Q2 FY26, a sequential increase of 120 bps.
- DSPS revenue grew 39% YoY to $56.6M; NGS revenue grew 12% YoY to $61.8M.
- Adjusted EBITDA loss of $(11.3)M vs $(8.0)M in the prior year period; company reiterates Q4 FY26 adjusted EBITDA breakeven.
- Cash and short-term investments stood at $167M as of June 30, 2026.
- GAAP net loss was $(35.1)M or $(0.56) per diluted share, compared to net income of $20.4M in Q3 FY25 which included a $48.8M gain from the spin-out of Atlas Data Storage.
Financial Impact
Revenue beat consensus by ~$3.9M (3.4%); FY guidance raised by ~$12M at the midpoint; gross margin expanded 120 bps sequentially.
Risk Factors
- GAAP net loss continues to widen on an absolute basis ($35.1M vs $20.4M net income in prior year, though prior year included a $48.8M one-time gain).
- Cash burn remains elevated; cash and short-term investments declined from $172M at March 31, 2026 to $167M at June 30, 2026.
- SG&A expenses grew 27% YoY to $80.7M, outpacing revenue growth of 23%.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001581280-26-000044 |
| Document: twist-20260803.htm | 0001581280-26-000044 |
| Document: 0001581280-26-000044-index-headers.html | 0001581280-26-000044 |
| Document: 0001581280-26-000044-index.html | 0001581280-26-000044 |
| Document: 0001581280-26-000044.txt | 0001581280-26-000044 |
| 8-K Data (Synthetic) | 0001581280-26-000044 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 21d ago | Insider Cluster | $127.22 $166.99 | ▲ +31.26% | ▲ +31.60% | $187.45 (+47.34%) |
Aug 27, 2026 5w ago | Insider Cluster | $153.10 $128.71 | ▼ −15.93% | ▼ −16.20% | $187.45 (+22.44%) |
Aug 25, 2026 5w ago | Insider Cluster | $151.42 $132.06 | ▼ −12.79% | ▼ −12.25% | $187.45 (+23.79%) |
Aug 21, 2026 6w ago | Insider Cluster | $145.59 $141.38 | ▼ −2.89% | ▼ −3.37% | $187.45 (+28.75%) |
Aug 20, 2026 6w ago | Insider Cluster | $136.23 $153.10 | ▲ +12.38% | ▲ +11.27% | $187.45 (+37.60%) |
Aug 14, 2026 6w ago | Insider Cluster | $124.41 $140.80 | ▲ +13.17% | ▲ +14.36% | $187.45 (+50.67%) |
Aug 14, 2026 6w ago | Insider Cluster | $124.41 $140.80 | ▼ −13.17% | ▼ −14.36% | $187.45 (−50.67%) |
Aug 12, 2026 7w ago | Insider Cluster | $125.29 $136.23 | ▲ +8.73% | ▲ +10.70% | $187.45 (+49.61%) |
Aug 12, 2026 7w ago | 144 | $125.29 $136.23 | ▲ +8.73% | ▲ +10.70% | $187.45 (+49.61%) |
Aug 11, 2026 7w ago | Insider Cluster | $123.12 $116.10 | ▼ −5.70% | ▼ −5.30% | $187.45 (+52.25%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access